Home » Topics » Immuno-oncology, BioWorld Science

Immuno-oncology, BioWorld Science
RSS

Promising preliminary phase I data for HER-2 Protein AutoVac vaccine

Nov. 24, 2003

New analysis of data from TNF-alpha AutoVac trial shows antibody levels

Nov. 20, 2003

Thalidomide approved for multiple myeloma and ENL in Australia

Nov. 19, 2003

Swiss prenotification of intent to approve Erbitux

Nov. 18, 2003

Dendreon grants Kirin HLA-DR antibody license, regains Asian Provenge rights

Nov. 18, 2003

ECOG phase III trial of Rituxan reaches primary efficacy endpoint early

Nov. 17, 2003

Two additional pivotal trials for IGN-101

Nov. 14, 2003

Immunomedics negotiating return of epratuzumab rights from Amgen

Nov. 13, 2003

Maxim seeks European approval for Ceplene treatment

Nov. 11, 2003

Final results for phase II study of R-1549 in gastric cancer

Nov. 10, 2003

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 30, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...